Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease

References

• Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479–501. doi:10.1146/annurev-physiol-012110-14225021054166
   PubMed Web of Science ®Google Scholar
• Fusetti F, von Moeller H, Houston D, et al. Structure of human chitotriosidase. Implications for specific inhibitor design and function of mammalian chitinase-like lectins. J Biol Chem. 2002;277(28):25537–25544. doi:10.1074/jbc.M20163620011960986
   PubMed Web of Science ®Google Scholar
• Boot RG, Bussink AP, Verhoek M, de Boer PAJ, Moorman AFM, Aerts JMFG. Marked differences in tissue-specific expression of chitinases in mouse and man. J Histochem Cytochem Off J Histochem Soc. 2005;53(10):1283–1292. doi:10.1369/jhc.4A6547.2005
   PubMed Web of Science ®Google Scholar
• Bussink AP, Speijer D, Aerts JMFG, Boot RG. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics. 2007;177(2):959–970. doi:10.1534/genetics.107.07584617720922
   PubMed Web of Science ®Google Scholar
• Adrangi S, Faramarzi MA. From bacteria to human: A journey into the world of chitinases. Biotechnol Adv. 2013;31(8):1786–1795. doi:10.1016/j.biotechadv.2013.09.01224095741
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Liu W, He CH, et al. Chitinase 3-like-1 promotes Streptococcus pneumoniae killing and augments host tolerance to lung antibacterial responses. Cell Host Microbe. 2012;12(1):34–46. doi:10.1016/j.chom.2012.05.01722817986
   PubMed Web of Science ®Google Scholar
• Marion CR, Wang J, Sharma L, et al. Chitinase 3-like 1 (Chil1) regulates survival and macrophage-mediated interleukin-1β and tumor necrosis factor alpha during pseudomonas aeruginosa pneumonia. Infect Immun. 2016;84(7):2094–2104. doi:10.1128/IAI.00055-1627141083
   PubMed Web of Science ®Google Scholar
• Wang H-L, Hsiao P-C, Tsai H-T, Yeh C-B, Yang S-F. Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients. Int J Mol Sci. 2013;14(11):22817–22825. doi:10.3390/ijms14112281724256818
   PubMed Web of Science ®Google Scholar
• Spoorenberg SMC, Vestjens SMT, Rijkers GT, et al. YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia. Respirol Carlton Vic. 2017;22(3):542–550. doi:10.1111/resp.12924
   PubMed Web of Science ®Google Scholar
• Østergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol. 2002;9(3):598–604. doi:10.1128/cdli.9.3.598-604.200211986266
   PubMedGoogle Scholar
• Gong Z, Xing S, Zheng F, Xing Q. Increased expression of chitinase 3-like 1 in aorta of patients with atherosclerosis and suppression of atherosclerosis in apolipoprotein E-knockout mice by chitinase 3-like 1 gene silencing. Mediators Inflamm. 2014;2014:905463. doi:10.1155/2014/90546324729664
   PubMed Web of Science ®Google Scholar
• Wu S, Hsu L-A, Cheng S-T, et al. Circulating YKL-40 level, but not CHI3L1 gene variants, is associated with atherosclerosis-related quantitative traits and the risk of peripheral artery disease. Int J Mol Sci. 2014;15(12):22421–22437. doi:10.3390/ijms15122242125486056
   PubMed Web of Science ®Google Scholar
• Di Rosa M, Malaguarnera L. Chitinase 3 like-1: an emerging molecule involved in diabetes and diabetic complications. Pathobiol J Immunopathol Mol Cell Biol. 2016;83(5):228–242. doi:10.1159/000444855
   Web of Science ®Google Scholar
• Buisson A, Vazeille E, Minet-Quinard R, et al. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43(10):1069–1079. doi:10.1111/apt.1358526953251
   PubMed Web of Science ®Google Scholar
• Nielsen KR, Steffensen R, Boegsted M, et al. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther. 2011;13(3):R109. doi:10.1186/ar339121714862
   PubMed Web of Science ®Google Scholar
• Sekine T, Masuko-Hongo K, Matsui T, et al. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis. 2001;60(1):49–54. doi:10.1136/ard.60.1.4911114282
   PubMed Web of Science ®Google Scholar
• Wcisło-Dziadecka D, Kotulska A, Brzezińska-Wcisło L, Kucharz EJ, Lis-Swiety A, Kamińska-Wiciorek G. Serum human cartilage glycoprotein-39 levels in patients with systemic lupus erythematosus. Pol Arch Med Wewn. 2009;119(12):777–784.
   Web of Science ®Google Scholar
• Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS. YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population: cohort and mendelian randomization studies. Clin Chem. 2014;60(11):1429–1440. doi:10.1373/clinchem.2014.22909625225167
   PubMed Web of Science ®Google Scholar
• Kumagai E, Mano Y, Yoshio S, et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6:35282. doi:10.1038/srep3528227739482
   PubMed Web of Science ®Google Scholar
• Rusak A, Jablonska K, Piotrowska A, et al. The role of CHI3L1 expression in angiogenesis in invasive ductal breast carcinoma. Anticancer Res. 2018;38(6):3357–3366. doi:10.21873/anticanres.1260229848684
   PubMed Web of Science ®Google Scholar
• Väänänen T, Kallio J, Vuolteenaho K, et al. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. Scand J Urol. 2017;51(5):367–372. doi:10.1080/21681805.2017.132788528644702
   PubMed Web of Science ®Google Scholar
• Salomon J, Piotrowska A, Matusiak Ł, Dzięgiel P, Szepietowski JC. Chitinase-3-like protein 1 (YKL-40) expression in squamous cell skin cancer. Anticancer Res. 2018;38(8):4753–4758. doi:10.21873/anticanres.1278330061245
   PubMed Web of Science ®Google Scholar
• Wan G, Xiang L, Sun X, et al. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget. 2017;8(3):5382–5391. doi:10.18632/oncotarget.1428028036271
   PubMedGoogle Scholar
• Gomez JL, Crisafi GM, Holm CT, et al. Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. J Allergy Clin Immunol. 2015;136(1):51–58.e10. doi:10.1016/j.jaci.2014.11.02725592985
   PubMed Web of Science ®Google Scholar
• Komi DEA, Kazemi T, Bussink AP. New insights into the relationship between chitinase-3-like-1 and asthma. Curr Allergy Asthma Rep. 2016;16(8):57. doi:10.1007/s11882-016-0637-227438466
   PubMed Web of Science ®Google Scholar
• Specjalski K, Chełmińska M, Jassem E. YKL-40 protein correlates with the phenotype of asthma. Lung. 2015;193(2):189–194. doi:10.1007/s00408-015-9693-y25663327
   PubMed Web of Science ®Google Scholar
• James AJ, Reinius LE, Verhoek M, et al. Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;193(2):131–142. doi:10.1164/rccm.201504-0760OC26372680
   PubMed Web of Science ®Google Scholar
• Lai T, Wu D, Chen M, et al. YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling. Respir Res. 2016;17:31. doi:10.1186/s12931-016-0338-327013031
   PubMed Web of Science ®Google Scholar
• Gumus A, Kayhan S, Cinarka H, et al. High serum YKL-40 level in patients with COPD is related to hypoxemia and disease severity. Tohoku J Exp Med. 2013;229(2):163–170.23364142
   PubMed Web of Science ®Google Scholar
• Létuvé S, Kozhich A, Arouche N, et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol Baltim Md 1950. 2008;181(7):5167–5173.
   Google Scholar
• Holmgaard DB, Mygind LH, Titlestad IL, et al. Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2013;13:77. doi:10.1186/1471-2466-13-7724373580
   PubMed Web of Science ®Google Scholar
• Létuvé S, Kozhich A, Humbles A, et al. Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am J Pathol. 2010;176(2):638–649. doi:10.2353/ajpath.2010.09045520042671
   PubMed Web of Science ®Google Scholar
• Long X, He X, Ohshimo S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J. 2017;49:2. doi:10.1183/13993003.01924-2015
   Web of Science ®Google Scholar
• Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis–a potential marker of disease activity? Respir Med. 2005;99(4):396–402. doi:10.1016/j.rmed.2004.09.01615763444
   PubMed Web of Science ®Google Scholar
• Kruit A, Grutters JC, Ruven HJT, van Moorsel CCM, van Den Bosch JMM. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med. 2007;101(7):1563–1571. doi:10.1016/j.rmed.2006.12.00617236752
   PubMed Web of Science ®Google Scholar
• Bargagli E, Maggiorelli C, Rottoli P. Human chitotriosidase: a potential new marker of sarcoidosis severity. Respir Int Rev Thorac Dis. 2008;76(2):234–238. doi:10.1159/000134009
   Web of Science ®Google Scholar
• Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 2010;104(8):1204–1210. doi:10.1016/j.rmed.2010.02.02620347285
   PubMed Web of Science ®Google Scholar
• Korthagen NM, van Moorsel CHM, Barlo NP, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011;105(1):106–113. doi:10.1016/j.rmed.2010.09.01220888745
   PubMed Web of Science ®Google Scholar
• Korthagen NM, van Moorsel CHM, Zanen P, Ruven HJ, Grutters JC. Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung. 2014;192(6):975–980. doi:10.1007/s00408-014-9647-925274153
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269–280. doi:10.1056/NEJM20000727343040710911010
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet Lond Engl. 2004;364(9435):709–721. doi:10.1016/S0140-6736(04)16900-6
   PubMed Web of Science ®Google Scholar
• Seibold MA, Donnelly S, Solon M, et al. Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and disease. J Allergy Clin Immunol. 2008;122(5):944–950.e3. doi:10.1016/j.jaci.2008.08.02318845328
   PubMed Web of Science ®Google Scholar
• Agapov E, Battaile JT, Tidwell R, et al. Macrophage chitinase 1 stratifies chronic obstructive lung disease. Am J Respir Cell Mol Biol. 2009;41(4):379–384. doi:10.1165/2009-0122R19491341
   PubMed Web of Science ®Google Scholar
• Sakazaki Y, Hoshino T, Takei S, et al. Overexpression of chitinase 3-like 1/YKL-40 in lung-specific IL-18-transgenic mice, smokers and COPD. PLoS One. 2011;6(9):e24177. doi:10.1371/journal.pone.002417721915293
   PubMed Web of Science ®Google Scholar
• Han S-S, Lee WH, Hong Y, et al. Comparison of serum biomarkers between patients with asthma and with chronic obstructive pulmonary disease. J Asthma Off J Assoc Care Asthma. 2016;53(6):583–588. doi:10.3109/02770903.2015.1056347
   PubMed Web of Science ®Google Scholar
• Shirai T, Hirai K, Gon Y, et al. Combined Assessment of Serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol Pract. 2019;7(1):134–145.e1. doi:10.1016/j.jaip.2018.06.01529981861
   PubMed Web of Science ®Google Scholar
• Otsuka K, Matsumoto H, Niimi A, et al. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respir Int Rev Thorac Dis. 2012;83(6):507–519. doi:10.1159/000330840
   Web of Science ®Google Scholar
• Gao J, Iwamoto H, Koskela J, et al. Characterization of sputum biomarkers for asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2457–2465. doi:10.2147/COPD.S11348427757028
   PubMed Web of Science ®Google Scholar
• Tworek D, Majewski S, Szewczyk K, et al. The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD. Respir Res. 2018;19(1):108. doi:10.1186/s12931-018-0807-y29859068
   PubMed Web of Science ®Google Scholar
• Majewski S, Pietrzak A, Tworek D, et al. Skin condition and its relationship to systemic inflammation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:2407–2415. doi:10.2147/COPD.S14180528860735
   PubMed Web of Science ®Google Scholar
• GOLD 2017. Global strategy for the diagnosis, management and prevention of COPD. Glob Initiat Chronic Obstr Lung Dis. 2016 Available from: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed August 12, 2018.
   Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• Majewski S, Cichocki P, Stępnicka-Bindemann M, Górski P. Asthma control, quality of life and successful sputum induction. Arch Med Sci. 2011;7(5):840–843. doi:10.5114/aoms.2011.2555922291829
   PubMed Web of Science ®Google Scholar
• Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax. 1997;52(6):498–501.9227713
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol. 2007;119(5):1043–1052;quiz 1053–1054. doi:10.1016/j.jaci.2007.02.042
   Web of Science ®Google Scholar
• Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586.3342669
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• Przybyłowski T, Tomalak W, Siergiejko Z, et al. Polish respiratory society guidelines for the methodology and interpretation of the 6 min walk test (6MWT). Pneumonol Alergol Pol. 2015;83(4):283–297. doi:10.5603/PiAP.2015.004826166790
   PubMedGoogle Scholar
• Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2009;77(3):305–313.19591105
   PubMedGoogle Scholar
• Kanneganti M, Kamba A, Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol. 2012;5:1–9.23439988
   PubMedGoogle Scholar
• Kawada M, Hachiya Y, Arihiro A, Mizoguchi E. Role of mammalian chitinases in inflammatory conditions. Keio J Med. 2007;56(1):21–27.17392594
   PubMedGoogle Scholar
• Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172–209.17087877
   PubMed Web of Science ®Google Scholar
• van Eijk M, van Roomen CPAA, Renkema GH, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol. 2005;17(11):1505–1512. doi:10.1093/intimm/dxh32816214810
   PubMed Web of Science ®Google Scholar
• Elias JA, Homer RJ, Hamid Q, Lee CG. Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma. J Allergy Clin Immunol. 2005;116(3):497–500. doi:10.1016/j.jaci.2005.06.02816159614
   PubMed Web of Science ®Google Scholar
• Malaguarnera L. Chitotriosidase: the yin and yang. Cell Mol Life Sci. 2006;63(24):3018–3029. doi:10.1007/s00018-006-6269-217075695
   PubMed Web of Science ®Google Scholar
• Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365(Pt 1):119–126. doi:10.1042/BJ2002007512071845
   PubMed Web of Science ®Google Scholar
• Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28(50):4456–4468. doi:10.1038/onc.2009.29219767768
   PubMed Web of Science ®Google Scholar
• Tong X, Wang D, Liu S, et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:409–418. doi:10.2147/COPD.S15265529430175
   PubMed Web of Science ®Google Scholar
• Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273(40):25680–25685.9748235
   PubMed Web of Science ®Google Scholar
• Kurt I, Abasli D, Cihan M, et al. Chitotriosidase levels in healthy elderly subjects. Ann N Y Acad Sci. 2007;1100:185–188. doi:10.1196/annals.1395.01717460177
   PubMed Web of Science ®Google Scholar
• Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta Int J Clin Chem. 2011;412(9–10):709–712. doi:10.1016/j.cca.2011.01.022
   PubMed Web of Science ®Google Scholar
• Matsuura H, Hartl D, Kang M-J, et al. Role of breast regression protein-39 in the pathogenesis of cigarette smoke-induced inflammation and emphysema. Am J Respir Cell Mol Biol. 2011;44(6):777–786. doi:10.1165/rcmb.2010-0081OC20656949
   PubMed Web of Science ®Google Scholar
• Verweij PE, Kerremans JJ, Voss A, Meis JF. Fungal contamination of tobacco and marijuana. JAMA. 2000;284(22):2875.11147983
   PubMed Web of Science ®Google Scholar
• Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39–47.18046901
   PubMedGoogle Scholar
• Eltboli O, Bafadhel M, Hollins F, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014;14:112. doi:10.1186/1471-2466-14-11225007795
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349. doi:10.2147/COPD.S15229129403271
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC21680942
   PubMed Web of Science ®Google Scholar
• Majewski S, Tworek D, Szewczyk K, et al. Overexpression of chitotriosidase and YKL-40 in serum and sputum in healthy smokers and patients with chronic obstructive pulmonary disease. Eur Respir J. 2018;52(suppl62):PA2022. doi:10.1183/13993003.congress-2018.PA2022
   Web of Science ®Google Scholar